Please wait while the transcript is being prepared...
0:00
Hello, I'm Peter Rossing,
I'm a Professor at University
of Copenhagen in Denmark and
also Head of
complications researchers
Steno Diabetes Copenhagen.
I'm going to talk about
proteomics in diabetic
kidney disease.
0:16
First, I'll share
my disclosures.
I worked with different
pharmaceutic companies
in relation to clinical trials.
Some of them are
relevant for today,
but most of them are not.
0:28
Diabetes is a major
problem globally.
Currently, 463 million
people are estimated to
have diabetes in 2019.
And this was expected to
rise to more than
700 million in 2045.
These numbers are rising
all over the world.
Approximately 90
percent of those with
diabetes have type two diabetes.
With more people
having diabetes,
more people are at risk for
kidney disease due to diabetes.
It's estimated that
approximately 40 percent of
those with diabetes have
some degree of chronic
kidney disease.
With more people
having diabetes,
more people have
chronic kidney disease.
Diabetes is actually
unfortunately,
so far the leading cause of
kidney failure around
most of the world.
1:19
We need to look out for
chronic kidney disease
or diabetic kidney disease
in people having diabetes.
As there are no symptoms,
this has to rely on
systematic screening.
Therefore, the American
Diabetes Association
and K-deal and
organization issuing
guidelines for treatment
of people with
chronic kidney disease have
made a consensus guidelines
saying we need to treat and
screen everybody for kidney
disease on a yearly basis.
If there's signs
of kidney damage,
that is increased albumin
creatinine ratio or
impaired kidney function that
is estimated glomerular
filtration rate,
or a combination
of this, well then
we need start intervention if
these impairments in
albuminuria or GFR
can be confirmed and are
sustained for more
than three months.
This has become
particularly important
because we have now today
more treatment
opportunities than
we've had in the past
than just during
very recent times
more treatment opportunities
have become apparent.
